Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5415-5422

  Zhao, Zhiming ^a   Li, Chenggang ^a   Xi, Hao ^b   Gao, Yuanxing ^a   Xu, Dabin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Shunyi Hospital Affiliated to China Medical University   (China)

Author keywords

Apoptosis; Curcumin; Forkhead box o1; Panc 1 cells; Pancreatic cancer; Phosphoinositide 3 kinase Akt pathway

Indexed keywords

CASPASE 3; CASPASE 9; CURCUMIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; FORKHEAD BOX O1; FORKHEAD TRANSCRIPTION FACTOR; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FOXO1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRDU ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; DNA REPAIR; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MTT ASSAY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRESS; WESTERN BLOTTING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84940572458     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4060     Document Type: Article

References (35)

1. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
2. Magee CJ, Ghaneh P and Neoptolemos JP: Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 16: 435-455, 2002.
3. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, et al: Pancreatic cancer. Curr Probl Cancer 26: 176-275, 2002.
4. Warshaw AL and Fernández-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
5. Fahy BN, Schlieman M, Virudachalam S and Bold RJ: AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89: 391-397, 2003.
6. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L and Bold RJ: Incidence, mechanismand prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115, 2003.
7. Huang H and Tindall DJ: Dynamic FoxO transcription factors. J Cell Sci 120: 2479-2487, 2007.
8. Gomes AR, Brosens JJ and Lam EW: Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 7: 3133-3136, 2008.
9. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW and Burgering BM: Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22: 2025-2036, 2002.
10. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM and Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842-7852, 2002.
11. Burgering BM and Medema RH: Decisions on life and death: FOXO forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73: 689-701, 2003.
12. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005.
13. Boreddy SR, Pramanik KC and Srivastava SK: Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res 17: 1784-1795, 2011.
14. Minami M, Nishio K, Ajioka Y, Kyushima H, Shigeki K, Kinjo K, Yamada K, Nagai M, Satoh K and Sakurai Y: Identification of Curcuma plants and curcumin content level by DNA polymorphisms in the trnS-trnfM intergenic spacer in chloroplast DNA. J Nat Med 63: 75-79, 2009.
15. Shehzad A, Lee J and Lee YS: Curcumin in various cancers. Biofactors 39: 56-68, 2013.
16. Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as 'Curecumin': From kitchen to clinic. Biochem Pharmacol 75: 787-809, 2008.
17. Sa G, Guo Y and Stacey DW: The regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 4: 618-627, 2005.
18. Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13: 2905-2927, 1999.
19. Manju V and Nalini N: Chemopreventive efficacy of ginger, a naturally occurring anticarcinogen during the initiation, post-initiation stages of 1, 2 dimethylhydrazine-induced colon cancer. Clin Chim Acta 358: 60-67, 2005.
20. Dorai T and Aggarwal BB: Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140, 2004.
21. Sinha R, Anderson DE, McDonald SS and Greenwald P: Cancer risk and diet in India. J Postgrad Med 49: 222-228, 2003.
22. Guo H, Xu YM, Ye ZQ, Yu JH and Hu XY: Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Pharmazie 68: 431-434, 2013.
23. Yin Z and Sun J: Curcumin induces human SKOV3 cell apoptosis via the activation of Rho-kinase. Eur J Gynaecol Oncol 35: 433-437, 2014.
24. Lv ZD, Liu XP, Zhao WJ, Dong Q, Li FN, Wang HB and Kong B: Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo. Int J Clin Exp Pathol 7: 2818-2824, 2014.
25. Dilnawaz F and Sahoo SK: Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur J Pharm Biopharm 85: 452-462, 2013.
26. Temraz S, Mukherji D and Shamseddine A: Potential targets for colorectal cancer prevention. Int J Mol Sci 14: 17279-17303, 2013.
27. Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models. Anticancer Res 32: 4843-4850, 2012.
28. Yogosawa S, Yamada Y, Yasuda S, Sun Q, Takizawa K and Sakai T: Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. J Nat Prod 75: 2088-2093, 2012.
29. Zhang X, Tang N, Hadden TJ and Rishi AK: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813: 1978-1986, 2011.
30. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H et al: Role of phosphatidylinositol 39-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178-4186, 2006.
31. Medema RH, Kops GJ, Bos JL and Burgering BM: AFX-like Forkhead transcription factors mediate cell cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787, 2000.
32. Seoane J, Le HV, Shen L, Anderson SA and Massagué J: Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223, 2004.
33. Evans-Anderson HJ, Alfieri CM and Yutzey KE: Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors. Circ Res 102: 686-694, 2008.
34. Katayama K, Nakamura A, Sugimoto Y, Tsuruo T and Fujita N: FOXO transcription factor-dependent p15 (INK4b) and p19 (INK4d) expression. Oncogene 27: 1677-1686, 2008.
35. Hamacher R, Schmid RM, Saur D and Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7: 64, 2008.